Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 3Not yet recruiting 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 544Neoplasms 384Carcinoma, Non-Small-Cell Lung 325Colorectal Neoplasms 296Lung Neoplasms 237Prostatic Neoplasms 220Carcinoma, Hepatocellular 213Stomach Neoplasms 155Pancreatic Neoplasms 155Leukemia, Myeloid, Acute 141Uterine Cervical Neoplasms 132Multiple Myeloma 130Recurrence 120Rectal Neoplasms 114Ovarian Neoplasms 109Neoplasm Metastasis 105Squamous Cell Carcinoma of Head and Neck 98Head and Neck Neoplasms 91Triple Negative Breast Neoplasms 87Esophageal Neoplasms 84Glioblastoma 82Endometrial Neoplasms 80Small Cell Lung Carcinoma 79Brain Neoplasms 79Colonic Neoplasms 78Melanoma 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 65Hematologic Neoplasms 65Glioma 63Disease 60

Interventions

Gemcitabine 2sintilimab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Pancreatic Cancer Resectable × Clear all
NCT07155629 2025-09-04

LEFT-PANC

Helsinki University Central Hospital

Phase 3 Not yet recruiting
381 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Zhejiang University

Phase 1/2 Not yet recruiting
60 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡